Eloralintide
Also called LY3841136; EloraTZP (combination with tirzepatide)
An investigational once-weekly amylin receptor agonist being developed by Lilly for obesity. Human trials show substantial average weight loss, and phase 3 studies are underway, but it is not approved.
Overview
What it is
A selective amylin receptor agonist. It is not a GLP-1 medicine. It is being studied alone and in combination with tirzepatide (EloraTZP).
How it works
Amylin is a hormone that promotes fullness and reduces calorie intake. Eloralintide targets this pathway instead of the GLP-1 pathway.
What the research shows
A 48-week phase 2 trial in 263 adults with obesity (no diabetes) reported average reductions up to 20.1% in the highest-dose group. A phase 2b trial of EloraTZP in 367 adults with type 2 diabetes reported 23.3% average reduction in the top arm versus 14.8% with tirzepatide alone, but discontinuations for side effects ran 10.8% to 27.0% versus 2.9%. Phase 3 trials ENLIGHTEN-1 (NCT07321886) and ENLIGHTEN-3 (sleep apnea) are ongoing.
Studied for
- Weight management without diabetesphase 2/3
- Weight in type 2 diabetes with tirzepatidephase 2b
- Obstructive sleep apneaphase 3
Safety and regulatory status
Safety and side effects
The most common side effects were digestive symptoms and fatigue, more frequent at higher doses and less frequent with slower escalation. Trials so far are too small and short to identify rare effects.
Regulatory status
Investigational as of October 2026. No approved US product.
Mixing and dosing reference
Reference information only. Read before using this section.
Eloralintide (10 mg Vial) Dosage Protocol
- Vial
- 10 mg Eloralintide
- Add diluent
- 1 mL
- Concentration
- 10 mg/mL
- 1 unit (U-100)
- 100 mcg in 0.01 mL
- Route
- Subcutaneous
Phase 2 Fixed-Dose Arms Using a 10 mg/mL Worked Preparation
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 48 weeks | 1 mg | 10 units (0.10 mL) |
| 48 weeks | 3 mg | 30 units (0.30 mL) |
| 48 weeks | 6 mg | 60 units (0.60 mL) |
| 48 weeks | 9 mg | 90 units (0.90 mL) |
How to mix
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 1.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with the compound, concentration, and reconstitution date. Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Protocol source: PeptideDosages.com
Common questions
Is eloralintide a GLP-1?
No. It targets amylin receptors. Tirzepatide adds GIP/GLP-1 activity in the combination.
Does "up to 20.1%" mean everyone loses that much?
No. That is the average of one trial group, not a prediction for any person.
Can I join a trial?
Check the sponsor's trial pages for current sites and eligibility.
Related in Metabolic Health
Sources and further reading (5)
- Eli Lilly. What to know about eloralintide (checked Oct 2026).
- Billings LK, et al. Eloralintide for obesity: a 48-week phase 2 trial. Lancet, 2025.
- Eli Lilly. EloraTZP phase 2b results, Sept 30, 2026 (sponsor announcement).
- ENLIGHTEN-1, NCT07321886.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).